You just read:

New analysis of INPULSIS™ trials demonstrates efficacy of OFEV® (nintedanib) across a range of IPF patients using broader diagnostic criteria

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

27 Jun, 2016, 08:00 ET